Effect of mirtazapine on thyroid hormones in adult patients with major depression

被引:14
作者
Gambi, F
De Berardis, D
Sepede, G
Campanella, D
Galliani, N
Carano, A
La Rovere, R
Salini, G
Penna, L
Cicconetti, A
Spinella, S
Quartesan, R
Salerno, RM
Ferro, FM
机构
[1] Univ G Annunzio Chieti, Inst Psychiat, Dept Oncol & Neurosci, I-66013 Chieti, Italy
[2] Univ Roma Tor Vergata, Psychiat Clin, Dept Neurosci, Rome, Italy
[3] Univ Perugia, Psychiat Clin, I-06100 Perugia, Italy
关键词
mirtazapine; major depression; thyroid hormones; long-term treatment;
D O I
10.1177/039463200501800417
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hormone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months of therapy. HAM-D scores decreased significantly from the first day of treatment to the end of the treatment period (P < 0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of treatment period (P=0.015) whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process of T4 into T3.
引用
收藏
页码:737 / 744
页数:8
相关论文
共 53 条
[11]   NEUROCHEMICAL AND AUTONOMIC PHARMACOLOGICAL PROFILES OF THE 6-AZA-ANALOGUE OF MIANSERIN, ORG-3770 AND ITS ENANTIOMERS [J].
DEBOER, T ;
MAURA, G ;
RAITERI, M ;
DEVOS, CJ ;
WIERINGA, J ;
PINDER, RM .
NEUROPHARMACOLOGY, 1988, 27 (04) :399-408
[12]   The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission [J].
deBoer, T .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :19-23
[13]   Macrophage-targeted photodynamic therapy [J].
Demidova, TN ;
Hamblin, MR .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2004, 17 (02) :117-126
[14]  
DUAL F, 1996, BIOL PSYCHIAT, V39, P643
[15]  
Duval F, 1996, ARCH GEN PSYCHIAT, V53, P833
[16]   Thyroid axis activity and serotonin function in major depressive episode [J].
Duval, F ;
Mokrani, MC ;
Bailey, P ;
Correa, H ;
Diep, TS ;
Crocq, MA ;
Macher, JP .
PSYCHONEUROENDOCRINOLOGY, 1999, 24 (07) :695-712
[17]   Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain [J].
Eravci, M ;
Pinna, G ;
Meinhold, H ;
Baumgartner, A .
ENDOCRINOLOGY, 2000, 141 (03) :1027-1040
[18]   Mirtazapine acutely inhibits basal and K+-stimulated release of corticotropin-releasing hormone from the rat hypothalamus via a non-genomic mechanism [J].
Fabricio, ASC ;
Tringali, G ;
Pozzoli, G ;
Navarra, P .
PSYCHOPHARMACOLOGY, 2005, 178 (01) :78-82
[19]  
FAVA M, 1995, J CLIN PSYCHIAT, V56, P186
[20]   Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial [J].
Fava, M ;
Dunner, DL ;
Greist, JH ;
Preskorn, SH ;
Trivedi, MH ;
Zajecka, J ;
Cohen, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (06) :413-420